Find the Perfect Plan for Your Investment Journey
C
Latest price
52 Week Range
€0.21 - €1.22
Next Earnings Date
Sep 25 2025 (Estimate)
Next Earnings Date
Sep 25 2025 (Est.)
Latest price
Market Cap | €19.89M |
EV | €16.59M |
Shares Outstanding | 41.89M |
Beta | 1.24 |
Analyst Rating | NOT_AVAILABLE |
Analyst Target Price | - |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | - |
EPS | 56.40% |
Operating Cash Flow | 40.30% |
Free Cash Flow | 62.20% |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | - |
ROCE 2024 | -170.92% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
C
Celyad Oncology SA
CYAD
Sector
Healthcare
Industry
Biotechnology
CEO
Kane, Matthew
Employees
18
Website
www.celyad.comIPO Date
2013-07-04
Headquarters
Axis Business Park, Rue AndrE Dumont 9, Mont-Saint-Guibert, Walloon Brabant, 1435, Belgium
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved